Physician profile
Mitchell S Schwartz
NPI 1174594089
$3,381.15
in general payments reported to CMS, 2019-2025
23 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $67.59 · 2021: $154 · 2022: $327 · 2023: $400 · 2024: $943 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,469 · Education: $44.65 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,469.09 |
| Education | $44.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $990.85 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $649.59 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $552.61 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $246.99 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.56 | 2024-2025 | Xifaxan |
| Gilead Sciences, INC. | $97.47 | 2019-2024 | |
| Fujifilm Healthcare Americas Corporation | $92.20 | 2024 | Fujifilm |
| Genzyme Corporation | $91.06 | 2024-2025 | |
| Daiichi Sankyo INC. | $84.79 | 2019-2024 | Injectafer |
| Celgene Corporation | $43.72 | 2023 | Zeposia |
| Ardelyx, INC. | $43.26 | 2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $37.46 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $36.31 | 2024-2025 | Voquezna |
| Intra-Sana Laboratories | $31.28 | 2024-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Madrigal Pharmaceuticals | $30.21 | 2025 | Rezdiffra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $27.16 | 2023 | Hadlima, Renflexis |
| Ferring Pharmaceuticals INC. | $26.82 | 2022 | |
| W. L. Gore & Associates, INC. | $21.52 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $18.98 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $17.91 | 2023 | |
| Alfasigma USA, INC. | $15.29 | 2022 | |
| Intercept Pharmaceuticals, INC. | $13.27 | 2019 | |
| Qol Medical, LLC | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.